

Haematologica
HAEMATOL/2016/151738
Version 3

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Gilles Salles, Stephen J. Schuster, Sven de Vos, Nina D. Wagner-Johnston, Andreas Viardot, Kristie A. Blum, Christopher R. Flowers, Wojciech J. Jurczak, Ian W. Flinn, Brad S. Kahl, Peter Martin, Yeonhee Kim, Sanatan Shreay, Matthias Will, Bess Sorensen, Madlaina Breuleux, Pier Luigi Zinzani, and Ajay K. Gopal

Disclosures: GS has received personal fees from Amgen, Celgene, Gilead Sciences, Inc., Janssen, Mundipharma, Novartis, and Roche and grants from Roche outside the submitted work. SJS has received research support from and served as a consultant to Gilead Sciences, Inc. NDW-J has served on an advisory board and speaker's bureau for Gilead Sciences, Inc. CRF has served as an unpaid consultant to Gilead Sciences, Inc. IWF has received research funding from Gilead Sciences, Inc. YK and SS are employed by Gilead Sciences, Inc. BS, MB, and MB were employed by Gilead Sciences, Inc. at the time this work was conducted. AKG has served as a consultant to Gilead.

Contributions: GS, SJS, SdV, NDW-J, AV, KAB, CRF, WJJ, IWF, BSK, PM, PLZ, and AKG were principal investigators. GS participated in the manuscript content development. BS and YK assisted in the data analyses. All authors reviewed the draft manuscript, provided critical feedback, and approved the final manuscript for submission to Haematologica.